Table 4.
Variable | Univariate analysis |
Multivariate analysis |
||||
---|---|---|---|---|---|---|
OR | 95% CI | p value | OR | 95% CI | p value | |
Female sex | 1.317 | 0.749–2.316 | 0.339 | |||
Age | 0.985 | 0.963–1.007 | 0.186 | |||
Body mass index | 1.052 | 0.953–1.161 | 0.319 | |||
Liver cirrhosis | 0.660 | 0.297–1.468 | 0.309 | |||
Type of therapy | ||||||
PEG-IFNα-2a | Reference | Reference | ||||
PEG-IFNα-2b | 1.950 | 1.094–3.473 | 0.023 | 3.019 | 1.426–6.390 | 0.004 |
Thyroid stimulating hormonea | 3.025 | 1.685–5.428 | < 0.001 | 2.088 | 1.961–8.767 | < 0.001 |
Anti-TPO Ab+ | 9.571 | 2.477–36.989 | 0.001 | 8.812 | 1.742–44.577 | 0.009 |
Anti-TG Ab+ | 4.912 | 1.528–15.812 | 0.008 | 2.389 | 0.564–10.124 | 0.237 |
OR, odds ratio; CI, confidence interval; PEG-IFN, pegylated interferon; Anti-TPO Ab, anti-thyroid peroxidase antibody; Anti-TG Ab, anti-thyroglobulin antibody.
≤ 2.03 mIU/mL vs. > 2.03 mIU/mL.